StreetInsider.com News Articles

Aclarion CEO Brent Ness to Attend LSI USA 2026

Thu, 12 Mar 2026 06:00:00 -0400

BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders.

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the

Aclarion CEO Brent Ness to Attend LSI USA 2026

Thu, 12 Mar 2026 06:00:00 -0400

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the

Aclarion CEO Brent Ness to Attend LSI USA 2026

Thu, 12 Mar 2026 06:00:00 -0400

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the

Aclarion CEO Brent Ness to Attend LSI USA 2026

Thu, 12 Mar 2026 06:00:00 -0400

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the

Aclarion CEO Brent Ness to Attend LSI USA 2026

Thu, 12 Mar 2026 06:00:00 -0400

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the

Aclarion CEO Brent Ness to Attend LSI USA 2026

Thu, 12 Mar 2026 06:00:00 -0400

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the

Aclarion says cash runway extends into 2028, ends equity facilities

Thu, 05 Feb 2026 06:00:52 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced it has sufficient cash to operate into 2028 and terminated its at-the-market equity offering program while allowing its equity line of credit to expire December 31, 2025.

The healthcare technology company released its 2026 shareholder letter outlining financial and operational priorities as it advances toward an initial internal readout of its 300-patient CLARITY trial expected at the end of the third quarter, with public disclosure of early interim results anticipated in the fourth quarter of 2026.

"Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial

Aclarion says cash runway extends into 2028, ends equity facilities

Thu, 05 Feb 2026 06:00:52 -0400

"Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial

Aclarion says cash runway extends into 2028, ends equity facilities

Thu, 05 Feb 2026 06:00:52 -0400

"Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial

Aclarion says cash runway extends into 2028, ends equity facilities

Thu, 05 Feb 2026 06:00:52 -0400

"Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Thu, 05 Feb 2026 06:00:00 -0400

Company anticipates no capital raises prior to expected value enhancing catalysts
Cash runway into 2028
ATM terminated in early 2025 and ELOC expired December 31, 2025

BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Thu, 05 Feb 2026 06:00:00 -0400

Company anticipates no capital raises prior to expected value enhancing catalysts
Cash runway into 2028
ATM terminated in early 2025 and ELOC expired December 31, 2025

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Thu, 05 Feb 2026 06:00:00 -0400

Company anticipates no capital raises prior to expected value enhancing catalysts
Cash runway into 2028
ATM terminated in early 2025 and ELOC expired December 31, 2025

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Thu, 05 Feb 2026 06:00:00 -0400

Company anticipates no capital raises prior to expected value enhancing catalysts
Cash runway into 2028
ATM terminated in early 2025 and ELOC expired December 31, 2025

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Thu, 05 Feb 2026 06:00:00 -0400

Company anticipates no capital raises prior to expected value enhancing catalysts
Cash runway into 2028
ATM terminated in early 2025 and ELOC expired December 31, 2025

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Thu, 05 Feb 2026 06:00:00 -0400

Company anticipates no capital raises prior to expected value enhancing catalysts
Cash runway into 2028
ATM terminated in early 2025 and ELOC expired December 31, 2025

Aclarion partners with Source Healthcare to expand Nociscan in Los Angeles

Tue, 03 Feb 2026 06:01:30 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced an agreement with Source Healthcare, an orthopedic and regenerative health clinic in Los Angeles, to provide access to its Nociscan diagnostic technology.

The partnership brings Nociscan to Source Healthcare's multidisciplinary team led by interventional pain management specialist Timothy T. Davis, MD. The collaboration aims to generate real-world evidence comparing Nociscan with anesthetic discography, a diagnostic spinal injection procedure used to identify specific spinal discs causing chronic pain.

Nociscan is a non-invasive diagnostic platform that measures pain and structural integrity biomarkers in spinal discs through magnetic resonance spectroscopy. The technology provides an alternative to anesthetic discography by

Aclarion partners with Source Healthcare to expand Nociscan in Los Angeles

Tue, 03 Feb 2026 06:01:30 -0400

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Tue, 03 Feb 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area
Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
Supports scalable growth strategy while building data assets critical to payer and provider adoption

BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Tue, 03 Feb 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area
Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Tue, 03 Feb 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area
Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Tue, 03 Feb 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area
Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Tue, 03 Feb 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area
Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Tue, 03 Feb 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area
Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Form 8-K Aclarion, Inc. For: Jan 09

Tue, 13 Jan 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260113/25841808.html